1 May 2020 08:00
1 May 2020
Appointment of Nominated Adviser and Joint Broker
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), the global pharmaceutical and services company, has appointed J.P.Morgan Cazenove as Nominated Adviser and Joint Broker with immediate effect. RBC Capital Markets will continue to act as the Company's Joint Broker.
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Nick Keher, Group Chief Financial Officer Matt Parrish, Head of Investor Relations |
|
|
|
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7742 4000 |
James Mitford / Hemant Kapoor |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
|
|
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Phillip Marriage | Email: clinigen@instinctif.com |
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com
CLIN.L (CLIN)